Ivosidenib

About

Therapy type: Targeted therapy

Therapy strategy: IDH1 inhibition

Mappings

NCI Thesaurus: Ivosidenib (coding:ncit:C114383)

RxNorm: ivosidenib (coding:rxcui:2049873, coding:omop:1560123)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (4) IDH1 p.R132C Acute Myeloid Leukemia Ivosidenib
FDA (4) IDH1 p.R132G Acute Myeloid Leukemia Ivosidenib
FDA (4) IDH1 p.R132H Acute Myeloid Leukemia Ivosidenib
FDA (4) IDH1 p.R132L Acute Myeloid Leukemia Ivosidenib
FDA (4) IDH1 p.R132S Acute Myeloid Leukemia Ivosidenib
EMA (1) FDA (2) IDH1 p.R132C Acute Myeloid Leukemia Azacitidine, Ivosidenib
EMA (1) FDA (2) IDH1 p.R132G Acute Myeloid Leukemia Azacitidine, Ivosidenib
EMA (1) FDA (2) IDH1 p.R132H Acute Myeloid Leukemia Azacitidine, Ivosidenib
EMA (1) FDA (2) IDH1 p.R132L Acute Myeloid Leukemia Azacitidine, Ivosidenib
EMA (1) FDA (2) IDH1 p.R132S Acute Myeloid Leukemia Azacitidine, Ivosidenib
FDA (2) IDH1 p.R132C Myelodysplastic Syndromes Ivosidenib
FDA (2) IDH1 p.R132G Myelodysplastic Syndromes Ivosidenib
FDA (2) IDH1 p.R132H Myelodysplastic Syndromes Ivosidenib
FDA (2) IDH1 p.R132L Myelodysplastic Syndromes Ivosidenib
FDA (2) IDH1 p.R132S Myelodysplastic Syndromes Ivosidenib
EMA (1) FDA (2) IDH1 p.R132C Cholangiocarcinoma Ivosidenib
EMA (1) FDA (2) IDH1 p.R132G Cholangiocarcinoma Ivosidenib
EMA (1) FDA (2) IDH1 p.R132H Cholangiocarcinoma Ivosidenib
EMA (1) FDA (2) IDH1 p.R132L Cholangiocarcinoma Ivosidenib
EMA (1) FDA (2) IDH1 p.R132S Cholangiocarcinoma Ivosidenib